Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Chmiel

Sleep Medicine E. Amherst, NY Medical Doctor

NPI 1508810581 CMS profile 719411

6041 Transit Rd, Suite 101, E. Amherst, NY 14051

Open in the dashboard

General payments

$29,883

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Chmiel of E. Amherst, NY is reported in the CMS Open Payments database as having received $29,883 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $248 6
2024 General $506 6
2023 General $405 9
2022 General $277 6
2021 General $1,113 7
2020 General $13,451 28
2019 General $13,885 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Chmiel
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to James Chmiel were reported at $248. Among 41 Sleep Medicine profiles paid that year, the median was $509 and the middle half received between $149 and $1,143.

Show as a table
Year James Chmiel Sleep Medicine median Middle half National median
2019 $13,885 $276 $99–$1,051 $163
2020 $13,451 $154 $53–$837 $114
2021 $1,113 $311 $144–$1,090 $132
2022 $277 $312 $80–$539 $149
2023 $405 $439 $154–$773 $160
2024 $506 $450 $149–$1,411 $164
2025 $248 $509 $149–$1,143 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $21,023 18 payments
  2. Acclarent, Inc $7,661 51 payments
  3. Integra LifeSciences Corporation $490 6 payments
  4. Aerin Medical Inc. $197 5 payments
  5. GlaxoSmithKline, LLC. $125 1 payment
  6. Intersect ENT, Inc. $106 2 payments
  7. OptiNose US, Inc. $99 1 payment
  8. Smith+Nephew, Inc. $93 1 payment
  9. Stryker Corporation $89 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $23,250 9 payments
  2. Travel and Lodging $3,543 4 payments
  3. Food and Beverage $3,090 73 payments
Products named General payments · program years 2019–2025
  1. TruDi Navigation System $7,504 10 payments
  2. SpinPlus Navigation $6,009 4 payments
  3. ACCLARENT NAVWIRE SINUS NAVIGATION GUIDEWIRE $1,541 8 payments
  4. TruDi Nav Suction $1,298 1 payment
  5. TruDi Nav Cable Rhinology Otology Laryngology Neurosurgery $1,298 1 payment
  6. ACCLARENT AERA $490 6 payments
  7. INSPIRA AIR $490 6 payments
  8. RELIEVA SPINPLUS NAV $490 6 payments
  9. TruDi Probe $490 6 payments
  10. TruDi NAV Cable Rhinology Laryngology $428 11 payments
  11. Other $1,703 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

327

Median for Otolaryngology: 297

Drug cost

$7,720

Median for Otolaryngology: $6,314

Branded share of claims

33.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 27 $3,766
Fluticasone Propionate Generic 75 $1,149
Ipratropium Bromide Generic 25 $838
Fluocinolone Acetonide Oil Generic 13 $579
Triamterene-Hydrochlorothiazid Triamterene/Hydrochlorothiazid Brand 18 $348
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 29 $234
Methylprednisolone Generic 20 $141
Omeprazole Generic 11 $117
Doxycycline Hyclate Generic 14 $97
Famotidine Generic 17 $90

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$7,457

Medicare's payments for the services billed

Medicare patients

59

Average age 77

Services billed

108

42 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 32%
Chronic kidney disease 29%
Diabetes 27%
Atrial fibrillation 25%
Depression 25%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record